Moderna Cancer Vaccine Success, Shares Dip Post-Rally

The Cliff News | 20 August 2026

Moderna's stock saw a notable decline of approximately 12% in pre-market trading on Thursday, a day after experiencing a dramatic 177% surge. This market reaction occurred despite positive news regarding a successful Phase 3 clinical trial for a personalized mRNA cancer vaccine developed in partnership with Merck.

The joint development, named intisomeran, met its primary endpoint in a Phase 3 trial. The vaccine was tested on melanoma patients who had previously undergone surgery to remove their tumors. The trial aimed to assess the efficacy of adding intisomeran to Merck's existing cancer drug, Keytruda.

Promising Trial Results

The trial revealed that patients receiving the combination therapy of intisomeran and Keytruda demonstrated a significant improvement in staying longer without their cancer recurring or spreading, compared to those who received Keytruda alone. This outcome is viewed as a critical milestone for Moderna, signifying its ambition to diversify its business beyond its well-known COVID-19 vaccine portfolio.

Experts have lauded the trial's success. Dr. Ezekiel Emanuel described the results as “a home run, maybe even a grand slam” in comments made to Yahoo Finance, highlighting the potential impact of this advancement in cancer treatment.

Market Reassessment Post-Rally

The substantial one-day jump in Moderna's stock price on Wednesday was driven by investor enthusiasm following the positive trial news. However, the subsequent dip on Thursday suggests a market recalibration. Investors are now weighing the implications of this success on the company's future business prospects and earnings.

This market behavior indicates that the Thursday decline does not necessarily reflect a failure of the cancer vaccine results. Instead, it points to investors reassessing the extent to which the potential for future growth has already been factored into the stock's valuation after the significant rally.